Bayer/Onyx Pharma’s Nexavar Among MHLW’s Pre-Golden Week Approval Rush
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare's drug approval advisory body, the Pharmaceutical Affairs and Food Sanitization Council's second committee on new drugs April 27 recommended Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) for approval for the additional indication of advanced hepatocellular carcinoma
You may also be interested in...
Second sorafenib failure comes three months after Synta/GlaxoSmithKline’s elesclomol blow-up in the tough-to-crack cancer.
The complicated deal bolsters Genzyme’s developing oncology franchise and provides a potential MS blockbuster without requiring an up-front payment.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).